Biotherapy Services Limited
We understand many of you will have concerns about the current outbreak of Covid19 and we want to reassure you we are doing all we can to continue to work normally. Our team are working in our own home offices as per government advice and we are staying safe and connected. These are such exceptional times and we as a company have an absolute mission to deliver to the NHS and the global Health economy our ground breaking treatment.
This crisis is unprecedented in so many ways, but our NHS will prevail and we will overcome this. There will be some tough periods but we will continue with our important work outside of the current trial and provide services to front line clinicians who need our support and this specialist treatment.
We can still answer any questions if you need don’t hesitate to contact us. Email us firstname.lastname@example.org
Biotherapy Services Ltd. is a specialist pharmaceutical biotech company. We use state-of-the-art technology and patented proprietary processes, working to GMP (Good Manufacturing Practice) pharmaceutical manufacturing standards, to produce a range of clinically safe and effective autologous biotherapies for a broad range of clinical conditions.
Our RAPID™ Biodynamic Haematogel wound care treatment has been defined by the MHRA as the first-in-world, first-in-class wound care treatment, classified as a medicine.
The MHRA have approved the commencement of the RAPID-1 Diabetic Foot Ulcer Trial ISRCTN55474813 at the The Royal London Hospital, Barts Health NHS Trust.
For further information please contact us
Biotherapy Services Ltd. are a multidisciplinary team of clinicians, scientists, pharmacists and healthcare professionals focused on the delivery of safe and effective autologous biotherapies for a range of clinical applications. Autologous biotherapies enhance your own bodies wound healing and tissue regeneration capabilities.
We provide GMP (Good Manufacturing Practice) pharmaceutical standard services to support clinical specialists in the use of novel autologous biotherapies. Our particular focus is wound healing, tissue regeneration, using stem cells derived from autologous fat grafts and growth factors from cPRP.
Concentrated platelet-rich plasma (cPRP) is an autologous product derived from whole blood through the process of centrifugation and cellular fractionation. Autologous cPRP has been shown to be safe and effective in promoting the natural processes of wound healing, soft tissue regeneration, bone and cartilage reformation.